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A crossover study was conducted to identify the best α1-adrenoceptor (α1AR) antagonist for individual 
patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia 
(BPH).  One hundred thirteen patients (mean age 70.8 years) were enrolled.  All patients met BPH clini-
cal study guidelines.  Seven agents were utilized: tamsulosin 0.2mg,  silodosin 8mg,  urapidil 60mg,  
naftopidil 50mg,  prazosin 1mg,  terazosin 2mg,  and doxazosin 1mg.  Patients were initially prescribed 
tamsulosin or silodosin for a week and then urapidil for a week.  Two weeks later,  they were pre-
scribed the better of the 2 agents for a week and a new agent for the next week.  This cycle was 
repeated until all 7 agents were tested.  Eﬃcacy was evaluated with the International Prostate 
Symptom Score.  The agent rankings were doxazosin (25 [22ｵ]),  silodosin (22 [19ｵ]),  urapidil (19 
[17ｵ]),  naftopidil (17 [15ｵ]),  terazosin (12 [11ｵ]),  tamsulosin (11 [10ｵ]),  prazosin (7 [6ｵ]).  Only 
12 patients (11ｵ) changed agents after the crossover study was completed.  The major reason was 
adverse events (83ｵ).  We found that each of the 7 α1AR antagonists has its own supporters.  Further,  
the one-week crossover study was useful in identifying the best agent for the treatment of each indi-
vidual with LUTS.
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he prevalence of lower urinary tract symptoms 
(LUTS) secondary to benign prostatic hyper-
plasia (BPH) increases with age.  Moderate to severe 
symptoms occur in 40 and 80ｵ of men over the ages 
of 60 and 80 years,  respectively [1].  The 2 main 
medications for management of BPH are α1-adreno-
ceptor (α1AR) antagonists (blockers) and 5α-reductase 
inhibitors (5-ARI).  5-ARI shrinks the prostate,  but 
this process usually takes 3 to 6 months.
　α1AR antagonists relax prostatic and bladder neck 
smooth muscle and relieve LUTS by improving blad-
der outlet obstruction.  α1AR antagonists have a rapid 
eﬀect,  usually within a few days for improving LUTS.  
Therefore,  α1AR antagonists are considered the most 
eﬀective monotherapy for the relief of LUTS,  irre-
spective of prostate size [2-4].  However,  not all 
α1AR antagonists work in all patients [2,  3,  5].  
Quite a few dissatisﬁed patients come to our clinic 
having tried 1 or 2 α1AR antagonists at other clinics.  
They often have better outcomes when they try other 
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α1AR antagonists.  It is well known that there are at 
least three α1-adrenoceptor subtypes,  α1A,  α1B and α1D,  
in human prostate tissues,  but their ratio varies 
among patients [6-9].  The aﬃnity of α1AR antago-
nists is also variable; therefore,  the eﬃcacy of α1AR 
antagonists diﬀers among patients.  Reports have 
compared 2 or 3 α1AR antagonists or the eﬀects of 
combinations of other medications (e.g.  anticholinergics) 
[10],  but their results are not consistent.  To date,  no 
report has compared more than 4 α1AR antagonists 
[11-14].  This study is the ﬁrst report to compare 7 
α1AR antagonists.
　 Compatibility between patients and agents may be 
deﬁned by the genetic background [9].  Adverse 
events are also crucial factors for patients.  If one 
agent is very eﬀective but its associated adverse 
events are not tolerable,  it is not the best agent.  As 
clinicians,  we would like to prescribe the best agent 
as soon as possible.  We have utilized a crossover 
method to identify the best agent among 7 α1AR 
antagonists.  Here,  we report the results and beneﬁts 
of this method.
Materials and Methods
　 One hundred and forty-eight patients were included 
in this study.  Thirty-ﬁve patients were excluded from 
this study: 4 patients dropped out from the study 
because they found satisfaction with an agent before 
the crossover study completed,  and 31 patients had 
features that were not compatible with clinical study 
guidelines.  Therefore,  113 patients (mean age,  70.8 
years; range,  50-80 years) with LUTS suggestive of 
BPH were enrolled in the crossover study.  All 
patients met BPH clinical study guidelines: ｧ50 
years of age,  International Prostate Symptom Score 
(IPSS) ｧ8,  quality of life (QOL) index ｧ2,  prostate 
size ｧ20mL,  maximum urinary ﬂow rate (Qmax) 
＜15mL/s,  postvoid residual volume (PVR) ＜100mL.  
Qmax was analyzed when the voided volume was 
ｧ130mL (N＝94).  Seven agents were utilized in this 
study: tamsulosin 0.2mg once daily,  silodosin 4mg 
twice daily,  urapidil 30mg twice daily,  naftopidil 
50mg once daily,  prazosin 0.5mg twice daily,  tera-
zosin 1mg twice daily,  and doxazosin 1mg once daily 
(Table 1).  Each of these doses is the recommended 
dose in Japanese men.  No generic agents were used.
　 Patients were initially prescribed tamsulosin or 
silodosin for a week and urapidil for the next week 
(tamsulosin,  silodosin and naftopidil cannot be pre-
scribed at the same time according to the Japanese 
health care system).  Two weeks later,  they were 
prescribed the better of those agents for a week and a 
new agent for the following week.  This cycle was 
repeated until all 7 agents were tested.  There was no 
withdrawal period (washout) when the patients 
switched agents.  The superiority of agents was based 
on patient satisfaction.  If it was diﬃcult to judge 
superiority,  the agents were judged as “equal. ”
　 Eﬃcacy was evaluated with the IPSS after the 
patient had been receiving therapy with the self-cho-
sen best agent for 8 weeks.  Prostate volume was 
measured by transrectal ultrasound (TRUS).  Qmax 
and PVR were also recorded.  During the study,  other 
medications were not changed.
　 Values are reported as the means ± standard 
deviations (SDs).  The Wilcoxon signed rank test was 
used to compare the pre and post treatment IPSS,  
QOL,  Qmax,  and PVR,  and a p-value less than 0.05 
was considered signiﬁcant.  Institutional review board 
approval was obtained for this study (AUC IRB No.  2).
Results
　 Patient characteristics are summarized in Table 2.  
The mean IPSS was 18.0±6.4,  and the mean QOL 
index was 4.7±1.1.  The mean prostate volume was 
44.1±23.7mL.  The mean Qmax was 10.7±4.1mL/s.  
The mean residual urine volume was 36.0±30.4mL.
　 At the end of the crossover study,  there were 183 
rankings of best agents,  because some patients ranked 
ｧ2 agents as “equal. ” The agent rankings were dox-
azosin (40 [22ｵ]),  silodosin (36 [20ｵ]),  terazosin 
(31 [17ｵ]),  urapidil (23 [13ｵ]),  prazosin (20 [11ｵ]),  
naftopidil (19 [10ｵ]),  and tamsulosin (14 [8ｵ]) 
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Table 1　 α1-adrenoceptor antagonists tested in this study
Dose Subtype selectivity
1 Prazosin (Pra) 0.5mg　x2/day Non-selective
2 Urapidil (Ura) 30mg　x2/day Non-selective
3 Terazosin (Tera) 1mg　x2/day Non-selective
4 Doxazosin (Dox) 1mg　x1/day Non-selective
5 Tamsulosin (Tam) 0.2mg　x1/day α1A＞D＞＞B
6 Naftopidil (Naf) 50mg　x1/day α1D＞A＞＞B
7 Silodosin (Silo) 4mg　x2/day α1A＞＞D, B
(Fig.  1A).  On the other hand,  the order of the lower-
ranked agents (Nos.  4-7) was almost the reverse of the 
No.  1-ranked agents (data not shown).
　 Out of 183 agents chosen as best,  the 113 agents 
the patients continued to take were slightly diﬀerent.  
They were silodosin (26 [23ｵ]),  doxazosin (24 [21ｵ]),  
urapidil (18 [16ｵ]),  terazosin (15 [13ｵ]),  naftopi-
dil (12 [11ｵ]),  tamsulosin (11 [10ｵ]),  and prazosin 
(7 [6ｵ]) (Fig.  1B).  The major reasons they selected 
an “equal” No.  1 agent were the following: 1.  Adverse 
events (orthostatic hypotension) on terazosin,  pra-
zosin and doxazosin,  2.  Preference for once-daily 
agents over twice-daily agents.
　 A few months after they selected their No.  1 agent 
at the end of the crossover study,  12 patients (11ｵ) 
changed agents for various reasons.  As a result,  
silodosin decreased by 4ｵ,  terazosin decreased by 2ｵ,  
and naftopidil increased by 4ｵ (Fig.  1C).  Each agent 
had its own supporters.  The reasons patients changed 
agents were the following:
1.  Adverse events (8) (A.  orthostatic hypotension on 
doxazosin (1),  terazosin (1),  prazosin (1),  and 
silodosin (1); B.  nocturia (1) and rough ﬁnger (1) 
on terazosin; C.  nasal stuﬃness (1) and retrograde 
ejaculation (1) on silodosin).
2.  Insuﬃcient eﬀect with naftopidil (1) and silodosin 
(1).
3.  I and II (orthostatic hypotension and insuﬃcient 
eﬀect with doxazosin (1),  retrograde ejaculation 
and insuﬃcient eﬀect on silodosin (1)).
　 The IPSS was analyzed in 97 patients who com-
pleted it at baseline and 8 weeks after receiving the 
self-chosen best agent (Table 3).  The mean IPSS 
decreased by 3.8,  and the mean QOL index decreased 
by 1.6.  Each symptom domain analysis demonstrated 
that voiding symptoms (intermittency,  weak stream,  
straining) decreased by 1.4,  storage symptoms (fre-
quency,  urgency,  nocturia) decreased by 1.5,  and 
incomplete emptying decreased by 0.9.  Nocturia alone 
decreased by 0.6.  There were 24 to 61ｵ of unim-
proved patients on IPSS,  QOL or each IPSS domain.  
Qmax was analyzed in 64 patients who met the crite-
ria (voided volumeｧ130mL).  Qmax signiﬁcantly 
increased by 1.5mL/s.  PVR (78 patients) decreased 
by 1.1mL,  but it was not signiﬁcant (p＝0.93).
　 Table 4 shows the IPSS change stratiﬁed by 
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Table 2　 Patient characteristics
N Mean ± SD (range)
Age (years) 113 70.8 ± 8.6 (50-80)
IPSS 113 18.0 ± 6.4 (8-35)
QOL score 113 4.7 ± 1.1 (2-6)
Prostate volume (mL, TRUS) 113 44.1 ± 23.7 (20-153)
Qmax (mL/s)＊ 94 10.7 ± 4.1 (3.2-14.5)
Residual volume (mL) 113 36.0 ± 30.4 (0-95)
IPSS,  International Prostate Symptom Score; QOL,  quality of life;  
SD,  standard deviation; TRUS,  transrectal ultrasound.
＊Qmax was analyzed when urine volume was ｧ130mL.
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Fig. 1　 Best α1-adrenoceptor antagonists.  A,  183 agents including duplicates; B,  Best agent patients selected to continue at the end 
of the crossover study; C,  α1AR antagonists a few months after patients took (B) agents.  Non-selective agents are in gray and selective 
are in white.  Prazosin (Pra),  urapidil (Ura),  terazosin (Tera),  doxazosin (Dox),  tamsulosin (Tam),  naftopidil (Naf),  silodosin (Silo).
agent.  Total IPSS improvements were considerable 
(＞4.5) with doxazosin,  terazosin and tamsulosin.  
QOL index improvement was considerable (＞1.8) with 
prazosin,  doxazosin and urapidil.  Voiding symptom 
improvements were considerable with naftopidil and 
silodosin.  Storage symptom improvements were con-
siderable with tamsulosin,  terazosin and doxazosin.
　 Adverse events were identiﬁed on 86 occasions in 
49 patients (Table 5).  All adverse events were 
resolved by discontinuing the agents.  The incidence of 
adverse events was highest with silodosin (24ｵ),  and 
retrograde ejaculation accounted for 44ｵ of them.  
Orthostatic hypotension was seen frequently with 
terazosin,  prazosin,  urapidil and doxazosin.  Only 4 
of 16 patients with retrograde ejaculation discontin-
ued their agents.  However,  all patients with other 
adverse events discontinued their agents.
Discussion
　 There are currently 8 α1AR antagonists available 
worldwide.  Alfuzosin is not available in Japan.  
Urapidil and naftopidil are not available in western 
countries.  Djavan et al.  carried out a meta-analysis of 
4 α1AR antagonists (tamsulosin,  doxazosin,  terazosin,  
and alfuzosin).  They concluded that the eﬃcacy of 
these 4 α1AR antagonists was similar [15].  American 
Urological Association (AUA) and European Urological 
Association (EUA) guidelines support these data [3,  
5].  However,  their eﬃcacy diﬀers among individuals.  
Therefore,  in daily clinical practice,  we switch agents 
when one is not eﬀective.  However,  existing cross-
over studies are based on up to 3 agents.  Shouldnʼt we 
test all available agents? This question led us to con-
duct the current study.
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Table 3　 IPSS and objective parameters at baseline and after 8 weeks of administration of the agent each patient selected
(1) IPSS
IPSS domain 1 2 3 4 5 6 7
IPSS QOL score
Voiding
symptoms＊
Storage
symptoms＊＊
Incomplete
emptying
Frequency Intermittency Urgency
Weak
stream
Straining Nocturia
a. Baseline
mean±SD 18±6.3 4.8±1.1 8.6±3.5 7.0±3.5 2.4±1.8 2.8±1.8 2.3±1.8 1.7±1.6 4.2±1.1 2.1±1.8 2.5±1.3
range 8 - 35 2 - 6 0 - 15 1 - 15 0 - 5 0 - 5 0 - 5 0 - 5 0 - 5 0 - 5 0 - 5
b. After treatment
mean±SD 14.2±5.8 3.1±1.4 7.2±3.2 5.5±2.8 1.5±1.3 2.1±1.3 1.9±1.5 1.5±1.1 3.7±1.3 1.6±1.3 1.9±1.1
range 3 - 28 0 - 6 1 - 15 1 - 12 0 - 5 0 - 5 0 - 5 0 - 4 0 - 5 0 - 5 0 - 5
c. Improvement 3.8±6.3 1.6±1.5 1.4±3.3 1.5±3.4 0.9±1.8 0.7±1.7 0.4±1.8 0.2±1.6 0.5±1.4 0.5±1.6 0.6±1.1
(%) 21 35 16 21 38 25 17 12 12 24 24
d. Unimproved
　patients (%)＊＊＊
30 24 37 39 42 43 57 61 59 59 52
P value (a v.s. b) ＜0.0001 ＜0.0001 ＜0.0001 ＜0.001 ＜0.0001 ＜0.001 ＜0.05 0.23 ＜0.001 ＜0.01 ＜0.0001
＊Voiding symptoms,  IPSS domain (3, 5, 6); ＊＊Storage symptoms,  IPSS domain (2, 4, 7); ＊＊＊Unimproved patients,  patients with 
unchanged or increased IPSS score.
 N＝97
(2) Maximum ﬂow rate (Qmax (mL/sec))
a. Baseline
mean±SD 9.3±3.1
range 2.7 - 14
b. After treatment
mean±SD 10.8±2.9
range 3.7 - 14
c. Improvement 1.5±3.5
(%) 16
P value (a v.s. b) ＜0.0001
 N＝64,  who voided ｧ130mL both at baseline and after treatment
(3) Residual Urine Volume (mL)
a. Baseline
mean±SD 36.6±32.4
range 0 - 95
b. After treatment
mean±SD 35.5±27.3
range 0 - 95
c. Improvement 1.1±33.8
(%) 3
P value (a v.s. b) 0.93
 N＝78
　 A patient evaluates a medication based on what 
bothers him the most.  For example,  when nocturia is 
the main problem,  the patient will not be happy if his 
urinary stream improved but his nocturia did not 
change.  Objective evaluations,  such as Qmax and 
PVR change,  depend on patient health status and 
storage volume.  Therefore,  we utilized patient satis-
faction as the primary evaluation.  To determine the 
best agents in a short period of time,  the test period 
per agent was set at 1 week,  and there was no wash-
out period.
　 We learned 2 things from this study:
1.  There were no agents without any supporters.
　 Kojima et al.  quantiﬁed α1AR subtype expression 
in the prostate of men with LUTS by reverse tran-
scriptase-polymerase chain reaction (RT-PCR) [8,  
9].  They demonstrated that the mRNA expression 
levels of α1AR-subtypes in BPH tissue diﬀered among 
patients and that genetic diﬀerences were responsible 
for the diverse responses to subtype-selective α1AR 
antagonists.  That report gives our study a scientiﬁc 
background.  However,  our results demonstrated that 
there was no diﬀerence in patient choice of non-
selective and selective agents (Table 1,  Fig.  1).  In 
fact,  there are more non-selective agents in the higher 
ranks.  For example,  Nos.  1,  3,  4,  and 5 in Fig.  1A 
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Table 4　 IPSS change by diﬀerent α1-adrenoceptor antagonists at baseline and after 8 weeks of administration of the patient-selected 
agent
IPSS domain 1 2 3 4 5 6 7
IPSS QOL score
Voiding
symptoms
Storage
symptoms
Incomplete
emptying
Frequency Intermittency Urgency
Weak
stream
Straining Nocturia
All
(N＝97)
－3.8±6.3 －1.6±1.5 －1.4±3.3 －1.5±3.4 －0.9±1.8 －0.7±1.7 －0.4±1.8 －0.2±1.6 －0.5±1.4 －0.5±1.6 －0.6±1.1
Silodosin
(N＝24)
－2.5±5.8 －1.1±1.4 －1.9±2.9 　0.0±3.1 －0.7±1.6 ＋0.1±1.5 －0.3±1.8 ＋0.2±1.6 －0.8±1.0 －0.8±1.0 －0.3±1.0
Doxazosin
(N＝22)
－5.1±6.6 －2.1±1.2 －1.5±3.3 －2.4±3.7 －1.2±1.6 －1.1±1.7 －0.7±1.6 －0.5±1.9 　0.0±1.7 －0.8±1.8 －0.8±1.1
Urapidil
(N＝14)
－3.0±5.7 －1.9±1.6 －0.9±3.6 －1.3±2.9 －0.9±1.7 －0.9±1.5 －0.4±2.1 －0.1±1.4 －0.7±1.1 ＋0.2±1.3 －0.2±1.3
Terazosin
(N＝14)
－4.8±7.5 －1.4±1.5 －0.9±3.1 －2.6±4.2 －1.4±2.0 －0.8±2.0 －0.5±1.9 －0.8±1.6 　0.0±1.0 －0.4±1.5 －1.0±1.0
Tamsulosin
(N＝9)
－4.7±7.2 －1.7±1.5 －1.2±4.2 －2.9±3.1 －0.6±2.0 －1.3±1.2 －0.1±2.4 －0.4±1.5 －1.1±1.6 　0.0±1.7 －1.1±1.3
Naftopidil
(N＝8)
－2.8±6.0 －1.6±1.9 －2.6±3.9 ＋0.1±2.5 －0.3±1.0 ＋0.3±1.4 －0.5±1.8 ＋0.5±1.3 －1.1±1.5 －1.0±1.6 －0.6±1.1
Prazosin
(N＝6)
－3.2±6.6 －2.2±1.6 －1.0±2.9 －1.7±2.7 －0.5±3.1 －1.2±1.3 ＋0.2±1.6 －0.5±1.6 －0.7±0.6 －0.5±1.6 0.0±0.6
Table 5　 Adverse events
N (%) Cardiovascular Gastrointestinal Retrograde ejaculation
Overactive 
bladder Others
Silodosin 27 (24%)  2  6 12 1 6
Terazosin 14 (12%)  8  1  2 1 2
Prazosin 12 (11%)  7  2  1 1 1
Urapidil 10 (9%)  5  2  2 1 0
Doxazosin 9 (8%)  6  1  1 1 0
Tamsulosin 8 (7%)  3  1  2 1 0
Naftopidil 7 (6%)  4  1  2 0 0
Total 86/791＊(11%) 35 14 22 6 9
(49 patients, 86 incidents)
＊7 (agents)×113 (patients)＝791
are non-selective agents.  This suggests that the mixed 
ratio of α1A,  α1B and α1D may be more important than 
the selectivity of subtypes.  More studies are needed 
to elucidate the reason for this result.
2.  A one-week crossover study is useful for patients 
to select the best agent,  although it has some limita-
tions with regard to the determination of adverse 
events.
　 Usually 4 to 12 weeks are used to evaluate α1AR 
antagonists [2,  3,  5,  11-20].  A one-week test may 
give an advantage to fast-working agents.  α1AR 
antagonists become eﬀective within 1 to 7 days [2,  
15,  17-22].  The t1/2 of α1AR antagonists is as short 
as＜20h.  Therefore,  a 1-week crossover study does 
not necessarily aﬀect patient evaluation.  However,  
one week is too short to evaluate adverse events.  
There were 12 patients (11ｵ) who changed agents a 
few months after the end of the crossover study.  Ten 
(83ｵ) changed because of adverse events.  This fact 
supports the conclusion that our study design is suﬃ-
cient or even better at identifying the most eﬀective 
agent without being aﬀected by adverse events.  In 
other words,  patients can select the best agent based 
on a 1-week crossover study.  If adverse events appear 
thereafter,  they can switch to the second best agent,  
and the frequency of this switch may be as low as 11ｵ.
　 Another reason we used a 1-week crossover study 
is that the safety of α1AR antagonists is well known,  
and their associated adverse events other than ortho-
static hypotension are trivial [2,  3,  11-13].  Even the 
rate of orthostatic hypotension in a large cohort study 
(N＝53,824) was between 3 and 4 per 10, 000 person-
days [23].  The adverse events were also trivial in our 
study,  as expected (Table 5).
　 Recently,  combination therapies with α1AR antago-
nists and 5α-reductase inhibitors have been reported 
[24,  25].  The MTOPS study demonstrated that 
doxazosin and ﬁnasteride reduced the long-term risk 
of acute urinary retention and the need for invasive 
therapy [24].  The CombAT study demonstrated that 
dutasteride and tamsulosin provided signiﬁcantly 
greater symptom beneﬁt than either monotherapy at 4 
years [26].  The eﬀects of 5α-reductase inhibitors 
also vary among individuals.  When combination ther-
apy is utilized,  a crossover test of α1AR antagonists 
may beneﬁt patients.
　 Our study focused on patient satisfaction.  Patient 
satisfaction is one of the ultimate goals in clinical 
practice.  We often see dissatisﬁed patients who have 
been on ineﬀective α1AR antagonists for years.  If 
patients are not satisﬁed with one agent,  we should try 
others.  Our crossover study is useful for identifying 
the best agents in a typical practice.  In conclusion,  
the optimal α1AR antagonist varies among patients.  
Each of the 7 α1AR antagonists had its own support-
ers.  A one-week crossover study was useful and eﬃ-
cient in identifying the best agent for each individual 
in the treatment of LUTS suggestive of BPH.
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